Rapid Ebola Test Validated in Field Trials
|
By LabMedica International staff writers Posted on 15 Jul 2015 |
At present, diagnosis of Ebolavirus disease requires transport of venipuncture blood to field biocontainment laboratories for testing by real-time reverse transcription polymerase chain reaction (RT-PCR), resulting in delays that complicate patient care and infection control efforts.
However, RT-PCR is a slow and complex test that comes with attached risks for the health care workers responsible for the collection, transportation and testing of the blood. The complexity and slow turnaround for this diagnostic have been blamed for delaying success in containing the Ebola epidemic.
An international team led by those at the Boston Children's Hospital (MA. USA) performed a rapid diagnostic test on fingerstick blood samples from 106 individuals with suspected Ebolavirus disease presenting at two clinical centers in Sierra Leone during February 2015. They compared the point-of-care rapid diagnostic test results with clinical real-time RT-PCR results (RealStar Filovirus Screen RT-PCR kit 1·0; altona Diagnostics GmbH; Hamburg, Germany) for venipuncture plasma samples tested in a Public Health England field reference laboratory.
The team also performed the rapid diagnostic ReEBOV Antigen Rapid Test (Corgenix; Broomfield, CO, USA), on whole blood and real-time RT-PCR on plasma, on 284 specimens in the reference laboratory, which were submitted to the laboratory for testing from many clinical sites in Sierra Leone. In point-of-care testing, all 28 patients who tested positive for Ebolavirus disease by RT-PCR were also positive by fingerstick rapid diagnostic test and 71 of 77 patients who tested negative by RT-PCR were also negative by the rapid diagnostic test. In laboratory testing, all 45 specimens that tested positive by RT-PCR were also positive by the rapid diagnostic test, and 214 of 232 specimens that tested negative by RT-PCR were also negative by the rapid diagnostic test.
The authors concluded that the ReEBOV rapid diagnostic test had 100% sensitivity and 92% specificity in both point-of-care and reference laboratory testing in this population. With two independent readers, the test detected all patients who were positive for Ebolavirus by altona real-time RT-PCR; however, this benchmark itself had imperfect sensitivity. The study was published on June 26, 2015, in the journal the Lancet.
Related Links:
Boston Children's Hospital
altona Diagnostics GmbH
Corgenix
However, RT-PCR is a slow and complex test that comes with attached risks for the health care workers responsible for the collection, transportation and testing of the blood. The complexity and slow turnaround for this diagnostic have been blamed for delaying success in containing the Ebola epidemic.
An international team led by those at the Boston Children's Hospital (MA. USA) performed a rapid diagnostic test on fingerstick blood samples from 106 individuals with suspected Ebolavirus disease presenting at two clinical centers in Sierra Leone during February 2015. They compared the point-of-care rapid diagnostic test results with clinical real-time RT-PCR results (RealStar Filovirus Screen RT-PCR kit 1·0; altona Diagnostics GmbH; Hamburg, Germany) for venipuncture plasma samples tested in a Public Health England field reference laboratory.
The team also performed the rapid diagnostic ReEBOV Antigen Rapid Test (Corgenix; Broomfield, CO, USA), on whole blood and real-time RT-PCR on plasma, on 284 specimens in the reference laboratory, which were submitted to the laboratory for testing from many clinical sites in Sierra Leone. In point-of-care testing, all 28 patients who tested positive for Ebolavirus disease by RT-PCR were also positive by fingerstick rapid diagnostic test and 71 of 77 patients who tested negative by RT-PCR were also negative by the rapid diagnostic test. In laboratory testing, all 45 specimens that tested positive by RT-PCR were also positive by the rapid diagnostic test, and 214 of 232 specimens that tested negative by RT-PCR were also negative by the rapid diagnostic test.
The authors concluded that the ReEBOV rapid diagnostic test had 100% sensitivity and 92% specificity in both point-of-care and reference laboratory testing in this population. With two independent readers, the test detected all patients who were positive for Ebolavirus by altona real-time RT-PCR; however, this benchmark itself had imperfect sensitivity. The study was published on June 26, 2015, in the journal the Lancet.
Related Links:
Boston Children's Hospital
altona Diagnostics GmbH
Corgenix
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Microbiology News
- New Sensitive Blood Assay Detects Tuberculosis Antigen Directly in Blood
- High-Throughput Automated Platform to Advance Latent Tuberculosis Testing
- Expanded Diagnostics and Therapies Target Rising Gonorrhea Resistance
- New Rapid Ebola Antigen Test Detects Infection at Point of Care
- Syndromic GI Panel Detects Cyclospora for Rapid Case Confirmation
- Rapid Panel Identifies Gram-Negative Pathogens and Resistance Markers in Bloodstream Infections
- Bacterial Growth Assay Predicts COVID-19 Severity From Plasma
- Gut Microbiome Analysis Identifies Frailty-Related Signatures in Older Adults
- CE-Marked Blood Assay Automates Tuberculosis Infection Testing
- Genomic Surveillance Algorithm Improves Early Detection of Emerging Variants
- Rapid Gastrointestinal PCR Panels Deliver One-Hour Results
- H. pylori Screening Within Colorectal Program Aids Gastric Cancer Prevention
- Machine Learning Reveals Consistent Gut Microbiome Patterns in Colorectal Cancer
- Study Reveals Widespread Community Spread of Drug-Resistant Klebsiella
- Stronger Laboratory Services Support Timely Melioidosis Diagnosis Amid Global Spread
- Extracellular Vesicle Biomarker May Enable Noninvasive Monitoring of H. pylori
Channels
Clinical Chemistry
view channel
Blood Test Enters UK Primary Care Pathway for Earlier Alzheimer’s Diagnosis
Alzheimer’s disease is often first suspected in primary care, yet definitive evaluation frequently depends on specialized imaging or cerebrospinal fluid testing. This creates a persistent gap between disease... Read more
Machine Learning Model Shows Promise for Improving Metanephrine Testing Accuracy
Pheochromocytomas and paragangliomas are rare tumors that form in or near the adrenal glands and cause overproduction of stress hormones. Plasma-free metanephrines are the recommended first-line test,... Read moreMolecular Diagnostics
view channel
AI Tool Improves Long-Read Detection of Cancer Mutations
Accurate identification of somatic mutations remains difficult, particularly in structurally complex genomic regions. Short-read sequencing pipelines can miss clinically relevant variants, limiting research... Read more
FDA Clears Molecular Test for Bacterial Vaginosis and Candida Vaginitis
Vaginitis is a common reason for clinical visits, with bacterial vaginosis and Candida vaginitis among the leading causes. Overlapping symptoms and reliance on microscopy, pH testing, and clinical observation... Read moreHematology
view channel
Age-Specific CBC Reference Intervals Support Pediatric Diagnosis in Vietnam
Complete blood count (CBC) results underpin pediatric evaluation for anemia, infection, inflammation, and platelet disorders. Yet laboratories in Vietnam have largely relied on reference intervals derived... Read more
Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma
Minimal residual disease (MRD) monitoring is pivotal in multiple myeloma, where persistent malignant plasma cells drive relapse risk and help guide therapy decisions. In the United States, approximately... Read moreImmunology
view channel
Study Reveals Immune Mechanism Driving Severe COVID-19 Progression
Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more
Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read morePathology
view channel
AI Pathology Tool Predicts Relapse Risk in Stage II Colorectal Cancer
Bowel cancer is Australia’s fourth most commonly diagnosed cancer and the second leading cause of cancer death, while remaining the third most common cancer worldwide. In stage-two disease, determining... Read more
AI Pathology Tool Stratifies Rectal Cancer to Guide Chemoradiotherapy
Choosing intensified regimens for locally advanced rectal cancer is challenging because these therapies can cause serious side effects. Colorectal cancer is the fourth-most fatal cancer in the UK, and... Read more
PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers
Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read moreTechnology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channelLumiQuick Advances Oxidative Stress Research with Expanded AOXRE Portfolio
LumiQuick Diagnostics, Inc. (Santa Clara, CA, USA) has announced the addition of the AOXRE product line to its portfolio and introduced expanded services to help biotechnology and diagnostic companies... Read more
Collaboration Advances Sputum-Based Diagnostics for Asthma and COPD
Asthma and chronic obstructive pulmonary disease are highly prevalent inflammatory airway conditions, affecting more than 40 million Americans and more than 650 million people worldwide.... Read more





.jpg)



